Featured Research

from universities, journals, and other organizations

Drug Decreases Blood Vessel Stiffness In Older People

Date:
September 4, 2001
Source:
NIH/National Institute On Aging
Summary:
A novel drug that breaks down collagen bonds in the body’s blood vessels significantly decreases the stiffness of vessels in older people, according to a study conducted by National Institute on Aging (NIA) scientists and others. The finding suggests the medication could be a new treatment for high blood pressure, heart failure, and certain complications of diabetes.

A novel drug that breaks down collagen bonds in the body’s blood vessels significantly decreases the stiffness of vessels in older people, according to a study conducted by National Institute on Aging (NIA) scientists and others.* The finding suggests the medication could be a new treatment for high blood pressure, heart failure, and certain complications of diabetes.

ALT-711 (Alteon, Ramsey, New Jersey), a thiazolium-based compound, snips bonds or crosslinks created in the arteries and other tissues when glucose attaches to the protein collagen. Crosslinks are cable-like structures that inhibit the natural flexibility of collagen strands. They tend to proliferate with age. Crosslinks appear to toughen tissues and may contribute to some of the deterioration associated with aging and diabetes, such as elevated systolic blood pressure, stiff arteries, and impaired kidney function.

Independent data from the NIA’s Baltimore Longitudinal Study of Aging identifies vascular stiffness as perhaps the most important predictor of mortality from heart disease. The ability to reduce vascular stiffness could have a major influence on reducing deaths from heart disease.

For the study, investigators at nine U.S. clinical centers recruited 93 people over the age of 50 who showed evidence of vascular stiffening, including high systolic blood pressure (greater than 140 mm Hg) and pulse pressure of at least 60 mm Hg.

The participants were randomly divided into two groups—those who received daily doses of ALT-711 and those who were given a placebo daily. After 56 days, arterial pulse pressure—the difference between systolic and diastolic blood pressures—was significantly reduced among those taking the drug compared to the placebo group. In addition, large artery compliance, a measure of artery wall flexibility and blood volume capacity, improved 15 percent in the ALT-711 group compared to no improvement in the placebo group.

No significant drug side effects were noted in the study. Participants in the study who were taking medications to treat high blood pressure were allowed to continue taking these drugs as long as these treatments began at least four weeks before the study commenced and remained unchanged throughout the trial.

The study will appear online Monday at http://circ.ahajournals.org/rapidtrack.shtml as a "Rapid Track" publication of Circulation: Journal of the American Heart Association. The manuscript will be published in the Sept. 25th issue of the journal.

“Arterial stiffening is a major factor in many of the vascular diseases associated with advancing age,” said Edward Lakatta, M.D., co-author of the study and chief of the NIA’s Laboratory of Cardiovascular Sciences. “The significance of this drug is it alters the properties of the arterial wall and makes it easier for the heart to eject blood into the blood vessels. These results, coupled with prior studies in animals, certainly suggest that ALT-711 may be a safe and efficacious approach to decreasing the impact of arterial stiffness on cardiovascular health.”

The research was a joint effort by the NIA, Johns Hopkins University, and Alteon, Inc., as part of the Cooperative Research and Development Act, and was conducted in conjunction with multiple medical institutions.

The National Institute on Aging, one of 25 Institutes that constitute the National Institutes of Health, leads Federal efforts to support and conduct basic, clinical, epidemiological, and social research on aging and the special needs of older people. For more information about the NIA, visit the website at http://www.nih.gov/nia

*D.A. Kass, E.P. Shapiro, M. Kawaguchi, A.R. Capriotti, A. Scuteri, R.C. deGroof, and E.G. Lakatta, “Improved Arterial Compliance by a Novel Advanced Glycation End-Product Crosslink Breaker,” Circulation, 2001;104:r8-r14. A. Capriotti and Drs. Kass, Shapiro, and Kawaguchi are affiliated with Johns Hopkins Medical Institutions, Baltimore; Dr. Scuteri and Lakatta are affiliated with the Gerontology Research Center, National Institute on Aging, Baltimore; Dr. deGroof is employed by Alteon, Ramsey, N.J.


Story Source:

The above story is based on materials provided by NIH/National Institute On Aging. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute On Aging. "Drug Decreases Blood Vessel Stiffness In Older People." ScienceDaily. ScienceDaily, 4 September 2001. <www.sciencedaily.com/releases/2001/09/010904072709.htm>.
NIH/National Institute On Aging. (2001, September 4). Drug Decreases Blood Vessel Stiffness In Older People. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2001/09/010904072709.htm
NIH/National Institute On Aging. "Drug Decreases Blood Vessel Stiffness In Older People." ScienceDaily. www.sciencedaily.com/releases/2001/09/010904072709.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins